Skip to main content

Clinical Trials Using Paclitaxel

Review the clinical trials studying paclitaxel on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 199

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Status: Active
Location: 1021 locations
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Status: Active
Location: 1046 locations
Adding an Immunotherapy Drug, MEDI4736 (durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Status: Active
Location: 551 locations
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Status: Active
Location: 455 locations
Adding Nivolumab to Usual Treatment for People with Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Status: Active
Location: 359 locations
Testing the addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Status: Active
Location: 356 locations
Induction Pembrolizumab and Chemotherapy followed by Pembrolizumab before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation with Pembrolizumab followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Status: Active
Location: 316 locations
Chemotherapy Combined with Immunotherapy versus Immunotherapy alone for Older Adults with Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Status: Active
Location: 279 locations
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined with Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Status: Active
Location: 260 locations
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Status: Active
Location: 161 locations
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Status: Active
Location: 109 locations
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People with Advanced Head and Neck Cancer Who Cannot Receive Cisplatin
Status: Active
Location: 83 locations
Testing the Addition of Paclitaxel Administered into the Abdominal Cavity Combined with Chemotherapy for Patients with Gastric Cancer Spread to the Abdominal Cavity, STOPGAP II Trial
Status: Active
Location: 81 locations
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Status: Active
Location: 34 locations
Trastuzumab Emtansine Followed by Trastuzumab versus Paclitaxel in Combination with Trastuzumab for the Treatment of HER2-Positive Stage I Breast Cancer, ATEMPT 2.0 Trial
Status: Active
Location: 33 locations
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Location: 35 locations
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Status: Active
Location: 26 locations
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Status: Active
Location: 21 locations
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Status: Active
Location: 18 locations
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Status: Active
Location: 18 locations
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Status: Active
Location: 17 locations
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Status: Active
Location: 17 locations
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Status: Active
Location: 16 locations
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Status: Active
Location: 17 locations
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Status: Active
Location: 14 locations